Cargando…

Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six‐Month Results of a Placebo‐Controlled Trial

OBJECTIVE: To investigate the efficacy of 16‐week treatment with etanercept (ETN) in patients with suspected nonradiographic axial spondyloarthritis (SpA). METHODS: Tumor necrosis factor inhibitor–naive patients with inflammatory back pain with at least 2 SpA features and high disease activity (Bath...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rusman, Tamara, van der Weijden, Mignon A. C., Nurmohamed, Michael T., Landewé, Robert B. M., de Winter, Janneke J. H., Boden, Bouke J. H., Bet, Pierre M., van der Bijl, Carmella M. A., van der Laken, Conny, van der Horst‐Bruinsma, Irene E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251708/ https://www.ncbi.nlm.nih.gov/pubmed/33277982 http://dx.doi.org/10.1002/art.41607

Ejemplares similares

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis
por: van der Heijde, Désirée, et al.
Publicado: (2014)

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial
por: Walsh, Jessica A., et al.
Publicado: (2022)

Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky
por: Rusman, T., et al.
Publicado: (2018)

Determinants of the Physician Global Assessment of Disease Activity and Influence of Contextual Factors in Early Axial Spondyloarthritis
por: Hirano, Fumio, et al.
Publicado: (2022)

Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?
por: Siebuhr, Anne Sofie, et al.
Publicado: (2018)

Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort
por: Abawi, Ozair, et al.
Publicado: (2017)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
por: Deodhar, Atul, et al.
Publicado: (2020)

Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?
por: Bakker, P. A. C., et al.
Publicado: (2019)

Imaging Outcomes for Axial Spondyloarthritis and Sensitivity to Change: A Five‐Year Analysis of the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2022)

Progression From Subclinical Inflammation to Overt Spondyloarthritis in First‐Degree Relatives of Patients in Association With HLA–B27: The Pre‐Spondyloarthritis Cohort
por: de Jong, Henriëtte M. Y., et al.
Publicado: (2022)

Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life
por: Imkamp, Maike, et al.
Publicado: (2018)

Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter
por: Li, Zhixiu, et al.
Publicado: (2022)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort
por: Nikiphorou, Elena, et al.
Publicado: (2021)

Inflammation of the Sacroiliac Joints and Spine and Structural Changes on Magnetic Resonance Imaging in Axial Spondyloarthritis: Five‐Year Data From the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Supervised Group Exercise in Axial Spondyloarthritis: Patients' Satisfaction and Perspective on Evidence‐Based Enhancements
por: Hilberdink, Bas, et al.
Publicado: (2020)

Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
por: Sepriano, Alexandre, et al.
Publicado: (2017)

Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis
por: Stal, Rosalinde, et al.
Publicado: (2022)

Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
por: Turina, Maureen C, et al.
Publicado: (2017)

Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?: Data from the SPACE cohort
por: Rubio Vargas, Roxana, et al.
Publicado: (2016)

Do fatty lesions explain the effect of inflammation on new syndesmophytes in patients with radiographic axial spondyloarthritis? Results from the SIAS cohort and ASSERT trial
por: Stal, Rosalinde, et al.
Publicado: (2023)

Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
por: Regel, Andrea, et al.
Publicado: (2017)

Good construct validity of the CT Syndesmophyte Score (CTSS) in patients with radiographic axial spondyloarthritis
por: Stal, Rosalinde, et al.
Publicado: (2023)

Measuring quality of life of patients with axial spondyloarthritis for economic evaluation
por: Hernandez Alava, Monica, et al.
Publicado: (2022)

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
por: Kiltz, Uta, et al.
Publicado: (2020)

The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW
por: van der Horst-Bruinsma, Irene, et al.
Publicado: (2020)

Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
por: Boel, Anne, et al.
Publicado: (2021)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

No relationship between bone mineral density and syndesmophyte formation at the same level in the lumbar spine of patients with radiographic axial Spondyloarthritis
por: Marques, Mary Lucy, et al.
Publicado: (2020)

Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis
por: de Winter, Janneke J, et al.
Publicado: (2019)

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis
por: van der Heijde, D., et al.
Publicado: (2017)

Recurrence of axial spondyloarthritis among first-degree relatives in a prospective 35-year-follow-up family study
por: van der Linden, Sjef M, et al.
Publicado: (2022)

Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five‐Year Results From the DESIR Cohort
por: Ramiro, Sofia, et al.
Publicado: (2019)

Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study
por: Boel, Anne, et al.
Publicado: (2022)

Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ucl0c210f22oaq5c1cpfumofpa